FDA Extends Review of Eisai/Biogen LEQEMBI IQLIK Subcutaneous Injection as Alzheimer's Starting Dose
Tags Research · Enterprise
The FDA extended by three months its priority review of the supplemental Biologics License Application for LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease, pushing the PDUFA action date to August 24, 2026. Eisai and Biogen announced the FDA requested additional information during review, which constituted a major amendment, but has not raised any concerns about approvability. LEQEMBI IQLIK is a once-weekly subcutaneous formulation of lecanemab, an anti-amyloid beta monoclonal antibody. The subcutaneous maintenance dosing was approved by FDA on August 26, 2025. The current application seeks to expand the once-weekly subcutaneous formulation to initial (starting) treatment, which would offer greater flexibility in anti-amyloid treatment delivery. LEQEMBI is approved in 53 countries.
Technical significance
The FDA extension is a routine regulatory event rather than a negative signal, as the companies stated the FDA raised no concerns about approvability. The expansion of LEQEMBI IQLIK to a starting dose would simplify the treatment pathway by allowing patients to begin with subcutaneous injections rather than IV infusions, potentially improving adoption and reducing healthcare system burden. The August 24 PDUFA date gives a clear timeline for the decision.